Shared on03 Sep 25Fair value Increased 1.92%
Merck’s analyst price target edged up to $101.75, driven by positive sentiment around the Verona Pharma acquisition’s boost to the respiratory portfolio, ongoing digital and oncology partnerships, and stable vaccine outlook. Analyst Commentary Bullish analysts point to Merck’s $10B acquisition of Verona Pharma, seeing Verona’s Ohtu as a strategic anchor drug to expand Merck’s respiratory franchise and enhance competitiveness against major therapeutics in the space.
Shared on30 Apr 25Fair value Increased 2.05%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Decreased 2.29%
AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.
Shared on16 Apr 25Fair value Decreased 0.36%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 1.06%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.21%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 0.20%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 10%
AnalystConsensusTarget has decreased revenue growth from 5.6% to 4.5%.